Cargando…

Estimating the lifelong health impact and financial burdens of different types of lung cancer

BACKGROUND: Owing to the high mortality and rapidly growing costs related to lung cancer, it is worth examining the health benefits of prevention for major types of lung cancer. This study attempts to quantify the quality-adjusted life expectancy (QALE), loss-of-QALE, and lifetime healthcare expendi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Szu-Chun, Lai, Wu-Wei, Su, Wu-Chou, Wu, Shang-Yin, Chen, Helen HW, Wu, Yi-Lin, Hung, Mei-Chuan, Wang, Jung-Der
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234193/
https://www.ncbi.nlm.nih.gov/pubmed/24308346
http://dx.doi.org/10.1186/1471-2407-13-579
_version_ 1782344808548794368
author Yang, Szu-Chun
Lai, Wu-Wei
Su, Wu-Chou
Wu, Shang-Yin
Chen, Helen HW
Wu, Yi-Lin
Hung, Mei-Chuan
Wang, Jung-Der
author_facet Yang, Szu-Chun
Lai, Wu-Wei
Su, Wu-Chou
Wu, Shang-Yin
Chen, Helen HW
Wu, Yi-Lin
Hung, Mei-Chuan
Wang, Jung-Der
author_sort Yang, Szu-Chun
collection PubMed
description BACKGROUND: Owing to the high mortality and rapidly growing costs related to lung cancer, it is worth examining the health benefits of prevention for major types of lung cancer. This study attempts to quantify the quality-adjusted life expectancy (QALE), loss-of-QALE, and lifetime healthcare expenditures of patients with different pathological types of lung cancer. METHODS: A national cohort consisting of 66,535 patients with pathologically verified lung cancer was followed for 13 years (1998–2010) to obtain the survival function, which was further extrapolated to lifetime. Between 2011 and 2012, EuroQol 5-dimension questionnaires were used to measure the quality of life (QoL) for 1,314 consecutive, cross-sectional samples. After multiplying the lifetime survival function by the utility values of QoL, we estimated the QALE and loss-of-QALE. We also collected the monthly healthcare expenditures, which included National Health Insurance-reimbursed and out-of-pocket direct medical costs, for 2,456 patients from 2005 to 2012. These values were multiplied by the corresponding survival probabilities to calculate lifetime healthcare expenditures after adjustments with medical care inflation rates and annual discount rates. RESULTS: The QALE for patients with small cell lung cancer, squamous cell carcinoma, and adenocarcinoma were 1.21, 2.37, and 3.03 quality-adjusted life year (QALY), with the corresponding loss-of-QALE of 13.69, 12.22, and 15.03 QALY, respectively. The lifetime healthcare expenditures were US$ 18,455 ± 1,137, 20,599 ± 1,787, and 36,771 ± 1,998, respectively. CONCLUSIONS: The lifelong health impact and financial burdens in Taiwan are heavier for adenocarcinoma than for squamous cell carcinoma. The cost-effectiveness of prevention programs could be directly compared with that of treatment strategies to improve patient value. And the methodology could be applied to other chronic diseases for resources planning of healthcare services.
format Online
Article
Text
id pubmed-4234193
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42341932014-11-18 Estimating the lifelong health impact and financial burdens of different types of lung cancer Yang, Szu-Chun Lai, Wu-Wei Su, Wu-Chou Wu, Shang-Yin Chen, Helen HW Wu, Yi-Lin Hung, Mei-Chuan Wang, Jung-Der BMC Cancer Research Article BACKGROUND: Owing to the high mortality and rapidly growing costs related to lung cancer, it is worth examining the health benefits of prevention for major types of lung cancer. This study attempts to quantify the quality-adjusted life expectancy (QALE), loss-of-QALE, and lifetime healthcare expenditures of patients with different pathological types of lung cancer. METHODS: A national cohort consisting of 66,535 patients with pathologically verified lung cancer was followed for 13 years (1998–2010) to obtain the survival function, which was further extrapolated to lifetime. Between 2011 and 2012, EuroQol 5-dimension questionnaires were used to measure the quality of life (QoL) for 1,314 consecutive, cross-sectional samples. After multiplying the lifetime survival function by the utility values of QoL, we estimated the QALE and loss-of-QALE. We also collected the monthly healthcare expenditures, which included National Health Insurance-reimbursed and out-of-pocket direct medical costs, for 2,456 patients from 2005 to 2012. These values were multiplied by the corresponding survival probabilities to calculate lifetime healthcare expenditures after adjustments with medical care inflation rates and annual discount rates. RESULTS: The QALE for patients with small cell lung cancer, squamous cell carcinoma, and adenocarcinoma were 1.21, 2.37, and 3.03 quality-adjusted life year (QALY), with the corresponding loss-of-QALE of 13.69, 12.22, and 15.03 QALY, respectively. The lifetime healthcare expenditures were US$ 18,455 ± 1,137, 20,599 ± 1,787, and 36,771 ± 1,998, respectively. CONCLUSIONS: The lifelong health impact and financial burdens in Taiwan are heavier for adenocarcinoma than for squamous cell carcinoma. The cost-effectiveness of prevention programs could be directly compared with that of treatment strategies to improve patient value. And the methodology could be applied to other chronic diseases for resources planning of healthcare services. BioMed Central 2013-12-05 /pmc/articles/PMC4234193/ /pubmed/24308346 http://dx.doi.org/10.1186/1471-2407-13-579 Text en Copyright © 2013 Yang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yang, Szu-Chun
Lai, Wu-Wei
Su, Wu-Chou
Wu, Shang-Yin
Chen, Helen HW
Wu, Yi-Lin
Hung, Mei-Chuan
Wang, Jung-Der
Estimating the lifelong health impact and financial burdens of different types of lung cancer
title Estimating the lifelong health impact and financial burdens of different types of lung cancer
title_full Estimating the lifelong health impact and financial burdens of different types of lung cancer
title_fullStr Estimating the lifelong health impact and financial burdens of different types of lung cancer
title_full_unstemmed Estimating the lifelong health impact and financial burdens of different types of lung cancer
title_short Estimating the lifelong health impact and financial burdens of different types of lung cancer
title_sort estimating the lifelong health impact and financial burdens of different types of lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234193/
https://www.ncbi.nlm.nih.gov/pubmed/24308346
http://dx.doi.org/10.1186/1471-2407-13-579
work_keys_str_mv AT yangszuchun estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer
AT laiwuwei estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer
AT suwuchou estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer
AT wushangyin estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer
AT chenhelenhw estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer
AT wuyilin estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer
AT hungmeichuan estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer
AT wangjungder estimatingthelifelonghealthimpactandfinancialburdensofdifferenttypesoflungcancer